Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001246135 | SCV001419475 | uncertain significance | Imerslund-Grasbeck syndrome | 2022-02-11 | criteria provided, single submitter | clinical testing | This sequence change replaces serine, which is neutral and polar, with tyrosine, which is neutral and polar, at codon 453 of the CUBN protein (p.Ser453Tyr). This variant is present in population databases (rs368630481, gnomAD 0.03%). This variant has not been reported in the literature in individuals affected with CUBN-related conditions. ClinVar contains an entry for this variant (Variation ID: 970549). Algorithms developed to predict the effect of missense changes on protein structure and function are either unavailable or do not agree on the potential impact of this missense change (SIFT: "Deleterious"; PolyPhen-2: "Possibly Damaging"; Align-GVGD: "Class C15"). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Fulgent Genetics, |
RCV002504359 | SCV002816670 | uncertain significance | Imerslund-Grasbeck syndrome type 1; Proteinuria, chronic benign | 2022-05-21 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV003294149 | SCV003996893 | uncertain significance | Inborn genetic diseases | 2023-03-28 | criteria provided, single submitter | clinical testing | The c.1358C>A (p.S453Y) alteration is located in exon 12 (coding exon 12) of the CUBN gene. This alteration results from a C to A substitution at nucleotide position 1358, causing the serine (S) at amino acid position 453 to be replaced by a tyrosine (Y). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Ce |
RCV003414065 | SCV004126503 | uncertain significance | not provided | 2023-01-01 | criteria provided, single submitter | clinical testing | CUBN: PM2 |